NIKKEI 225
39,667.07 +493.92 (+1.26%) HANG SENG
18,089.93 +17.03 (+0.09%) CRUDE OIL
80.87 +0.04 (+0.05%) GOLD FUTURES
2,312.50 -18.30 (-0.79%) DOW
39,145.60 +33.44 (+0.09%) Bitcoin GBP
48,254.75 -821.32 (-1.67%)
Innate Pharma S.A. (IPHP.XC)
| Previous close | 2.5650 |
| Open | 2.5550 |
| Bid | 2.5650 x N/A |
| Ask | 2.5900 x N/A |
| Day's range | 2.5550 - 2.5600 |
| 52-week range | 2.5550 - 3.3110 |
| Volume | |
| Avg. volume | 0 |
| Market cap | 207.229M |
| Beta (5Y monthly) | 0.71 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.7300 |
| Earnings date | 12 Sept 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Business WireNumber of Shares and Voting Rights of Innate Pharma as of June 10, 2024
MARSEILLE, France, June 18, 2024--Regulatory News: Pursuant to the article L. 233-8 II of the French "Code de Commerce" and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") releases its total number of shares outstanding as well as its voting rights as at June 10, 2024:
Business WireInnate Pharma Shares Updated Results From the Sanofi Developed Blood Cancer Phase 1/2 SAR443579/IPH6101 Trial
MARSEILLE, France, June 17, 2024--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") announced today that updated efficacy and safety results from the dose-escalation part of the Phase 1/2 study with SAR443579/IPH6101 (SAR'579), an investigational CD123 targeting NKp46/CD16-based Natural Killer Cell Engager (NKCE), from a joint research collaboration between Innate Pharma and Sanofi and ANKET® platform lead asset, were shared in an oral presentation
Business WireInnate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Mycosis Fungoides
MARSEILLE, France, June 04, 2024--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") announced favorable results from the Phase 2 TELLOMAK study with lacutamab in mycosis fungoides (MF). The results were presented at the ASCO 2024 Annual Meeting, in Chicago, Illinois.
